Partner With Us NRI

Company details

6M Return 8.81%
1Y Return 8.89%
Mkt Cap.(Cr) 83,050.90
Volume 22,809
Div Yield 0.48%
OI Chg %
Volume 22,809

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume

Our Research View

Trading recommendation

Data not found

Investment recommendation

Call Date

30 Jul 2022

Entry Price


Target Price



12-18 Month

Rapid Results

Q1FY23 Quarterly Result Announced for Cipla Ltd.

Pharmaceuticals firm Cipla Announced Q1FY23 Result :

  • Growth momentum continues across core therapies & markets with expansion in base profitability
  • One-India: Sustained momentum in core portfolio across branded prescription, trade generics and consumer health over last year; 9% YoY growth adjusted for covid portfolio
  • SAGA: Muted growth in South Africa (SA) private primary sales with recovery expected in Q2; strong secondary demand with SA private outperforming market
  • US business: Reported $155Mn in revenue and 10% YoY growth; steady momentum in core formulation business led by contribution from respiratory and peptide assets.
  • R&D investments stands at INR 274 crores or 5.1% of sales; Higher 4% YoY driven by ongoing clinical trials on a respiratory asset and other developmental efforts.

“I am pleased to see the sustained momentum across our key segments with strong secondary growth across geographies. The core portfolio momentum in One-India business continues to be robust driven by strong demand levers. Our US run rate continues to witness consistent traction in respiratory, complex generics and peptide portfolio. We are closely tracking upcoming complex launches in H2FY23. Our reported operating profitability of 21.3% is well within our full year guidance of 21-22% range and has grown double digit vs last year base EBITDA despite multiple cost headwinds. Our cost rigor and calibrated pricing actions have helped offset inflationary cost elements, insulate margins while maintaining high serviceability.” Umang Vohra MD and Global CEO, Cipla Ltd


Result PDF


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 20,841.69 Cr FV: 2.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 2,384.58 23,141.09
LAST 3M 49,521.50 -18,551.54
LAST 6M 129,719.68 -157,153.27
LAST 12M 215,295.98 -222,611.80


  • About Company
  • Company Info
  • Listing Info
  • Cipla Limited is a pharmaceutical company having a market capitalization of Rs. 73,307.57 crores as of 18th August 2021. The company was incorporated within the year 1935. It reported its consolidated revenue at Rs. 5,504.35 for the quarter ended June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 500087 and scrip code CIPLA, respectively. As of 18th August 2021, the shares of Cipla were trading at Rs. 908.85.

    Cipla is headquartered in Mumbai and produces products for various therapeutic areas, including cardiology, children’s health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious illnesses & critical care, malaria, and so on. The drug company primarily develops medicines to treat respiratory, disorders, arthritis, diabetes, weight control and depression, and other medical conditions. Cipla is the third-largest drug company within the country and is present in most countries within the European region, with DTMs in Germany, Norway, UK, and Spain. The company’s promoters hold a 36.72% stake of the total shareholding in the company in June 2021 as against 36.68% in June 2020 with zero pledge. However, the mutual funds holding has also decreased in the last 12 months, decreasing from 16.29% in June 2020 to 13.36% in June 2021, and over the last 3 months, it has decreased 1.28%.

    In June 2021, consolidated total revenue from operations grew 26.64% to Rs. 5,504.35 crores, against Rs. 4,346.16 crores within the corresponding quarter last year. The Indian major pharmaceutical has posted a 23.67% increase in the consolidated net profit of Rs. 714.72 crores, on strong sales performance during June 2021, it had posted a net profit of Rs. 577.91 Crores within the corresponding period of the previous fiscal. EBITDA rose 28% to Rs. 1,346 crores in June 2021, from Rs. 1,049 crores in June 2020. EBITDA margin improved 32 basis points to 24.5%, as against 24.1% in the year-ago period. EPS of the company was Rs. 8.86 as compared to Rs. 5.13 in March 2021. Cipla’s shares closed at 908.85 (NSE) on 18th August 2021 and have returned 18.83% over the last 12 months.

Read More

Registered Address

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Tel : 91-22-24826000
Email : cosecretary:cipla.com
Website : http://www.cipla.com


Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500087
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE059A01026

ICICIdirect Cipla Ltd FAQ

You can buy Cipla Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Cipla Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 08, 2022 04:01 PM the closing price of Cipla Ltd was ₹ 1,029.25.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 08, 2022 04:01 PM, the market cap of Cipla Ltd stood at ₹ 83,050.90.
The latest PE ratio of Cipla Ltd as of Aug 08, 2022 04:01 PM is 33.17
The latest PB ratio of Cipla Ltd as of Aug 08, 2022 04:01 PM is 0.25
The 52-week high of Cipla Ltd is ₹ 1,083.15 while the 52-week low is ₹ 850.00 .
According to analyst recommendations, Cipla Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote